Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma.
about
Venous thromboembolic diseaseVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsManagement of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016Identification of two portal vein tumor thrombosis associated proteins in hepatocellular carcinoma: protein disulfide-isomerase A6 and apolipoprotein A-I.High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patientsAutoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis.Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?Diffusion-Weighted MRI of Malignant versus Benign Portal Vein Thrombosis.FDG-Avid Portal Vein Tumor Thrombosis from Hepatocellular Carcinoma in Contrast-Enhanced FDG PET/CTAssessing risk of venous thromboembolism in the patient with cancer.Hepatocellular carcinoma with inferior vena caval and right atrial tumor thrombi and massive pulmonary artery embolism: A case report.Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population.Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?Diabetes mellitus is associated with the presence of metastatic spread at disease presentation in hepatocellular carcinoma.Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma.Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt.An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.Hepatobiliary Quiz (Answers)-15 (2015).Mobile right atrial thrombus with pulmonary thromboembolism in a patient with advanced hepatocellular carcinoma and disseminated tumor thrombosis.Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis.Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation.The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis.Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges.Deal a death blow! HCC in cirrhotics - thrombotic complications: their frequency, characteristics, and risk factors.Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial.Liver Transplantation for a Patient with Hepatocellular Carcinoma with Vascular Invasion and Exceeding Milan Criteria-Happy End Despite it all.D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosisPleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
P2860
Q24631121-B629E86C-D5F5-423A-BFD8-76BB682534ADQ26741697-8E92A1E4-6B75-4C37-AB82-E761CCB0C385Q28072595-6E21C3E2-9FFB-4AF0-B2FE-7F98CE86DA14Q33925676-C2E945A8-211F-4713-99A1-E25C73888308Q34160974-DA4171B8-8A3C-4CC1-8D1C-E1CA63A6D294Q36024830-A52427D0-7181-48C9-A9C8-BB38CA853798Q36248507-7A3CDAD6-89FD-4AEE-9C24-84D822C694F2Q37073548-8CFE445F-BA77-4C00-8BD2-59C0D7E4A622Q37077295-DA9B4CDE-0D21-43BA-9439-70868B1A7931Q37393394-C5B7DF49-B5AD-429E-B5D8-C9587CA5BF35Q37594113-40841094-3C12-4494-A0B3-B08ACE49B9D4Q37708145-140560F4-3EA7-4627-9A3D-A10F28F82F38Q37743519-D16ECB8D-A6D3-4F2D-8B97-623E73BA0DEBQ38052626-766F620D-512D-496B-81ED-D2C659226DE2Q38857017-1F4A8259-705C-4777-8B69-74EBB69D8751Q40369578-14EEE361-F628-4A6E-BEAF-53EF1D6F0AD2Q40706069-E69CBDA5-0E00-43FD-B892-CEAC341480E2Q42046081-AB6DF679-DD7D-4A65-A1C1-EBB75281FD65Q42149390-5416378A-9B64-489E-9256-0E1B881883DEQ46283204-164242AC-3AC9-4A75-9430-78BF50173A9BQ47151986-E1A3E6CC-8EA1-4E23-82BB-F4A35849889EQ51015921-5E8F26E3-FC49-4BD4-A9A0-E00EAA0EBECEQ53063406-C7746E58-14BD-4DA9-B14A-88D2CAE7F8E9Q53826596-1FF7D6B0-7EE2-4468-B879-8A49C0DB7E7FQ54235513-6469586F-A524-447A-BD68-719CAC7F61BFQ54389561-AF69C867-5D09-4580-B3F5-329C71CEB16DQ54773237-A87E9CD9-A63C-41DE-BC17-7B304D1AA1E3Q57484445-45BF201E-8122-4AB3-A0E7-DC288B0DD40EQ58693989-DE64D5A1-9FDF-4523-A8C7-206783099EA2
P2860
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@ast
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@en
type
label
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@ast
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@en
prefLabel
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@ast
Incidence, risk factors and co ...... s in hepatocellular carcinoma.
@en
P2093
P2860
P1433
P1476
Incidence, risk factors and co ...... es in hepatocellular carcinoma
@en
P2093
Adel Bozorgzadeh
Gregory C Connolly
Ollivier Hyrien
Parvez Mantry
P2860
P304
P356
10.1016/J.THROMRES.2007.10.009
P577
2007-11-28T00:00:00Z